Hypnotic and sedative drugs--anything new on the horizon?
Many studies of new intravenous sedative drugs have been published last year, including several phase I trials. This review provides a brief summary of these studies, with recommendations for selected reading. Remimazolam is a rapidly metabolized benzodiazepine. Early clinical trials confirm more rapid recovery compared with midazolam. Etomidate analogues can be designed with rapid metabolism and without adrenocortical suppression, but research is only at the preclinical stage. MR04A3 and AZD3043 are gamma-aminobutyric acid A agonists with phase I data, but the outlook for further development is uncertain. Pioneers of intravenous emulsions of volatile anesthetics continue their work. Many of the new sedative drugs were designed to undergo rapid metabolism. Remimazolam has great potential to enter clinical practice because of its rapid offset of action.